Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Lung Neoplasms

Carcinoma

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Hormones

Tubulin Modulators

Antimitotic Agents

IV variable dosages, days 1-5 every 21 days for duration of study

imexon

IV once every 21 days for duration of study

docetaxel

Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine the highest dose of imexon which can be given with a full dose of docetaxel, and to provide information to enable the design of a future study focused on one or more specific cancer types.

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Taxotere® (Docetaxel) in Previously Treated Inoperable Stage III and Stage IV Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic Previously Treated Breast Cancer or Hormone Refractory Prostate Cancer

AmpliMed Corporation

Symptoms and General Pathology

Neoplasm Metastasis

Neoplastic Processes

Evan Hersh, MD

AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.

Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy

Evan Hersh, VP Medical Affairs

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gemcitabine

Antimetabolites

30-60 minutes IV, days 1,8,15 every 28 days

gemcitabine

Mark Zalupski, MD

Steven Cohen, MD

AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma

Evan Hersh

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Neuroendocrine Tumor

Neuroepithelioma

Dacarbazine

DTIC

AMP-005 is a Phase 1b/2 clinical trial designed to evaluate whether the new drug, imexon, can be administered in combination with the approved drug, dacarbazine (DTIC), for the treatment of patients with stage III or IV inoperable melanoma. The Phase 1b part of the study is designed to determine whether the two drugs can be safely combined together, and the Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether adding imexon to DTIC can improve the outcome for melanoma patients versus the findings from prior clinical studies of DTIC alone.

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients	NCT00327288	Non-small Cell ... Breast Cancer Prostate Cancer	imexon docetaxel	18 Years -	AmpliMed Corporation
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy	NCT00327223	Neoplasm Metast...	imexon	18 Years -	AmpliMed Corporation
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma	NCT00327327	Pancreatic Aden...	imexon gemcitabine	18 Years -	AmpliMed Corporation
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients	NCT00327249	Multiple Myelom...	imexon	18 Years -	AmpliMed Corporation
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma	NCT00327600	Malignant Melan...	imexon DTIC	-	AmpliMed Corporation
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients	NCT00327249	Multiple Myelom...	imexon	18 Years -	AmpliMed Corporation

Spots Global Cancer Trial Database for imexon

Every month we try and update this database with for imexon cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for imexon

Every month we try and update this database with for imexon cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for imexon cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.